PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$6.28 -0.1  -2.0%

Last Trade - 19/01/22

Small Cap
Market Cap £134.1m
Enterprise Value £82.8m
Revenue £n/a
Position in Universe 4894th / 7398

PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series

Thu 1st October, 2020 1:30pm
For best results when printing this announcement, please click on link below:

FLORHAM PARK, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies and infectious disease vaccines based on the
Company’s proprietary Versamune(®) T-cell activating technology, today
announced their participation in Noble Capital Markets’ Virtual Road Show
Series, presented by Channelchek, scheduled for October 6, 2020.

The virtual road show will feature a corporate presentation from PDS Biotech
CEO, Frank Bedu-Addo, Ph.D., followed by a Q & A session proctored by Noble
Biotechnology Analyst Ahu Demir, Ph.D., featuring questions submitted by the

The live broadcast of the virtual road show is scheduled for October 6, 2020,
at 1 PM EDT. Registration is free, but is limited to 100 participants.
Register Here

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline
of cancer immunotherapies and infectious disease vaccines based on the
Company’s proprietary Versamune(®) T-cell activating technology platform.
Versamune(®) effectively delivers disease-specific antigens for in vivo
uptake and processing, while also activating the critical type 1 interferon
immunological pathway, resulting in production of potent disease-specific
killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered
multiple therapies, based on combinations of Versamune(®) and
disease-specific antigens, designed to train the immune system to better
recognize disease cells and effectively attack and destroy them. To learn
more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC /
FINRA registered broker-dealer, dedicated exclusively to serving underfollowed
small / microcap companies through investment banking, wealth management,
trading & execution, and equity research activities. Over the past 36 years,
Noble has raised billions of dollars for these companies and published more
than 45,000 equity research reports. www.noblecapitalmarkets.com email:

About Channelchek

Channelchek (.com) is a comprehensive investor-centric portal - featuring more
than 6,000 emerging growth companies - that provides advanced market data,
independent research, balanced news, video webcasts, exclusive c-suite
interviews, and access to virtual road shows. The site is available to the
public at every level without cost or obligation. Research on Channelchek is
provided by Noble Capital Markets, Inc., an SEC / FINRA registered
broker-dealer since 1984. www.channelchek.com email: contact@channelchek.com

Forward Looking Statements

This communication contains forward-looking statements (including within the
meaning of Section 21E of the United States Securities Exchange Act of 1934,
as amended, and Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the “Company”) and
other matters. These statements may discuss goals, intentions and expectations
as to future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company’s
management, as well as assumptions made by, and information currently
available to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as “may,” “will,”
“should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” and
other similar expressions among others. Statements that are not historical
facts are forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and uncertainties
and are not guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as a result
of various factors, including, without limitation: the Company’s ability to
protect its intellectual property rights; the Company’s anticipated capital
requirements, including the Company’s anticipated cash runway and the
Company’s current expectations regarding its plans for future equity
financings; the timing for the Company or its partners to initiate the planned
clinical trials for its lead assets, PDS0101; the successful implementation
of the Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101 and the Company’s
interpretation of the results and findings of such programs and collaborations
and whether such results are sufficient to support the future success of the
Company’s product candidates; the acceptance by the market of the
Company’s product candidates, if approved; the timing of and the
Company’s ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other action
with respect to, the Company’s product candidates; and other factors,
including legislative, regulatory, political and economic developments not
within the Company’s control, including unforeseen circumstances or other
disruptions to normal business operations arising from or related to COVID-19.
The foregoing review of important factors that could cause actual events to
differ from expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and elsewhere,
including the risk factors included in the Company’s annual and periodic
reports filed with the SEC. The forward-looking statements are made only as of
the date of this press release and, except as required by applicable law, the
Company undertakes no obligation to revise or update any forward-looking
statement, or to make any other forward-looking statements, whether as a
result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

James Salierno
The Ruth Group
Phone: +1 (646) 536-7028
Email: jsalierno@theruthgroup.com


GlobeNewswire, Inc. 2020
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.